Piramal Healthcare will invest $11 million in its Morpeth facility, UK, to triple its production capacity for hormonal products, including contraceptive pills and hormone replacement therapies.
The Morpeth facility was acquired by the Piramals from Pfizer in 2006. The plant’s expansion, in response to customer demand, will see production capacity increase by two billion tablets a year, the company said.
The facility will include formulation, package coating and tablet-making equipment, and expansion work will commence later this year.
It is expected to become operational in another 18 months, the company said.
The investment follows Piramal Healthcare’s recent announcement of investing $2.5 million in its FDA-approved Grangemouth site — also in the UK — to upgrade one of its antibody drug conjugate (ADC) manufacturing facilities.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.